GlassScriptPhysician profile
Steven C Copenhaver
NPI 1396784518
$13,103.27
in general payments reported to CMS, 2019-2025
31 companies · $818 in 2025
The $818 reported for 2025 was more than what 85% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,141 · 2020: $1,408 · 2021: $693 · 2022: $608 · 2023: $790 · 2024: $645 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,076.19 |
| Education | $177.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $8,298.43 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $863.28 | 2019-2025 | Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $763.80 | 2019-2025 | Dupixent |
| Genzyme Corporation | $427.73 | 2021-2025 | |
| Covis Pharma Gmbh | $396.27 | 2019-2022 | |
| Philips North America LLC | $357.48 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Abbvie INC. | $298.40 | 2021-2025 | Creon |
| Electromed, INC. | $241.25 | 2019-2025 | Smartvest |
| Baxter Healthcare | $222.12 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $166.64 | 2020-2025 | Arikayce |
| Glaxosmithkline, LLC. | $131.43 | 2019-2024 | Nucala |
| Novartis Pharmaceuticals Corporation | $126.50 | 2019-2020 | |
| Chiesi USA, INC. | $105.35 | 2019-2021 | |
| Amgen INC. | $87.03 | 2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $80.72 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $71.61 | 2024-2025 | Daybue |
| Alcresta Therapeutics, INC. | $62.00 | 2023-2024 | Relizorb |
| Sanofi Pasteur INC. | $60.91 | 2023-2024 | |
| Genentech USA, INC. | $51.86 | 2023-2024 | Xolair |
| Pharming Healthcare, INC. | $45.26 | 2023-2024 | Ruconest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.00 | 2022 | |
| Mylan Specialty L.P. | $35.88 | 2021-2023 | Tobi Podhaler |
| Pfizer INC. | $23.71 | 2023 | |
| Monaghan Medical Corporation | $22.58 | 2025 | Aerobika |
| Tactile Systems Technology INC | $22.24 | 2023 | Entre Plus, Flexitouch Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $20.58 | 2024 | Elaprase |
| Azurity Pharmaceuticals, INC. | $17.92 | 2025 | Alvesco |
| Teva Pharmaceuticals USA, INC. | $17.52 | 2021 | |
| Olympus America INC. | $17.03 | 2025 | Single-Use Flexible Video Bronchoscope |
| Pari Respiratory Equipment, INC. | $15.84 | 2019 | |
| Merck Sharp & Dohme LLC | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Copenhaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.